Discovery of caffeoylisocitric acid as a Keap1-dependent Nrf2 activator and its effects in mesangial cells under high glucose

References

• Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol 2019;15:327–45.
   PubMed Web of Science ®Google Scholar
• Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol 2011;1:1175–232.
   PubMed Web of Science ®Google Scholar
• Jha JC, Banal C, Chow BSM, et al. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal 2016;25:657–84.
   PubMed Web of Science ®Google Scholar
• Lee HB, Yu MR, Yang Y, et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14:S241–S5.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee N, Barma S, Konwar N, et al. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: an update. Eur J Pharmacol 2016;791:8–24.
   PubMed Web of Science ®Google Scholar
• Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 2005;1:27–40.
   PubMedGoogle Scholar
• Daehn I, Casalena G, Zhang T, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014;124:1608–21.
   PubMed Web of Science ®Google Scholar
• Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest 2014;124:2333–40.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017; 12:2032–45.
   PubMed Web of Science ®Google Scholar
• Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010;17:4256–69.
   PubMed Web of Science ®Google Scholar
• Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13:1665–78.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kensler TW, Motohashi H. The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol Rev 2018;98:1169–203.
   PubMed Web of Science ®Google Scholar
• Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244:21–6.
   PubMed Web of Science ®Google Scholar
• Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signalling in oxidative and reductive stress. Biochim. Biophys. Acta Mol Cell Res 2018;1865:721–33.
   PubMed Web of Science ®Google Scholar
• Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 2019;18:295–317.
   PubMed Web of Science ®Google Scholar
• de Haan JB. Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 2011;60:2683–4.
   PubMed Web of Science ®Google Scholar
• Wu X, Pan C, Chen R, et al. BML-111 attenuates high glucose-induced inflammation, oxidative stress and reduces extracellular matrix accumulation via targeting Nrf2 in rat glomerular mesangial cells. Int Immunopharmacol 2020;79:106108.
   PubMed Web of Science ®Google Scholar
• Canning P, Sorrell FJ, Bullock AN. Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med 2015;88:101–7.
   PubMed Web of Science ®Google Scholar
• Madden SK, Itzhaki LS. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery. Biochim Biophys Acta Proteins Proteom 2020; 1868:140405.
   PubMed Web of Science ®Google Scholar
• Tong KI, Katoh Y, Kusunoki H, et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol 2006;26:2887–900.
   PubMed Web of Science ®Google Scholar
• Tong KI, Padmanabhan B, Kobayashi A, et al. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 2007;27:7511–21.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki T, Kobayashi A, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008;28:2758–870.
   PubMed Web of Science ®Google Scholar
• Mou Y, Wen S, Li YX, et al. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors. Eur J Med Chem 2020;202:112532.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Chapman E. The role of natural products in revealing NRF2 function. Nat Prod Rep 2020;37:797–826.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Tuttle KR. New therapies for diabetic kidney disease. N Engl J Med 2013;369:2549–50.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi Z, Zhou Y, et al. Emerging substrate proteins of Kelch-like ECH associated protein 1 (Keap1) and potential challenges for the development of small-molecule inhibitors of the Keap1-nuclear factor erythroid 2-related factor 2 (Nrf2) protein-protein interaction. J Med Chem 2020;63:7986–8002.
   PubMed Web of Science ®Google Scholar
• Yao H, Zhang N, Zhang W, et al. Discovery of polypodiside as a Keap1-dependent Nrf2 activator attenuating oxidative stress and accumulation of extracellular matrix in glomerular mesangial cells under high glucose. Bioorg Med Chem 2020;28:115833.
   PubMed Web of Science ®Google Scholar
• Yao H, Zhang N, Zhang W, et al. Discovery of a coumarin derivative as Nrf2 activator mitigating oxidative stress and fibrosis in mesangial cells under high glucose. Bioorg Med Chem Lett 2020;30:127490.
   PubMed Web of Science ®Google Scholar
• Strack D, Leicht P, Bokern M, et al. Hydroxycinnamic acid esters of isocitric acid: accumulation and enzymatic synthesis in Amaranthus cruentus. Phytochemistry 1987;26:2919–22.
   Web of Science ®Google Scholar
• Li Y, Li K, Yao H. Chemical constituents from Potentilla fragarioides L. Biochem Syst Ecol 2020;93:104172.
   Web of Science ®Google Scholar
• Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;56:393–405.
   PubMed Web of Science ®Google Scholar
• Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology 2005;10:S7–S10.
   PubMed Web of Science ®Google Scholar
• Fakhruddin S, Alanazi W, Jackson KE. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J Diabetes Res 2017;2017:8379327.
   PubMed Web of Science ®Google Scholar
• Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol 2011;7:504–11.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028–40.
   PubMed Web of Science ®Google Scholar
• Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003;64:844–56.
   PubMed Web of Science ®Google Scholar
• Riser BL, Cortes P. Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis. Ren Fail 2001;23:459–70.
   PubMed Web of Science ®Google Scholar
• Fang S, Jin Y, Zheng H, et al. High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway. Mol Cell Biochem 2011;347:175–82.
   PubMed Web of Science ®Google Scholar
• Abed DA, Goldstein M, Albanyan H, et al. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B 2015; 5:285–99.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 2015;88:93–100.
   PubMed Web of Science ®Google Scholar
• Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev 2012;32:687–726.
   PubMed Web of Science ®Google Scholar